Results of the systematic review and meta-analysis support the use of pan-genotypic DAA regimens for the treatment of chronic HCV in adolescents and children ≥ 3 years of age.
Results highlight the benefit of achieving sustained virological response with DAAs for decreasing patients’ risk of carotid atherosclerosis and peripheral artery disease, especially among those with severe fibrosis.
The XGBoost machine learning model outperformed other AI and logistic regression models for predicting DAA failure, with an AUROC of 1.000 in the training dataset and 0.803 in the validation dataset.
Response to direct-acting antiviral therapy was similar between patients with and without HBV coinfection, with most patients completing the planned course of treatment and achieving SVR, even in the case of HBV reactivation.